Maxity Glaucoma Foundation, a non-governmental organisation, yesterday, described poor doctor-patient relationship in the country, particularly in terms of medical information on diseases, treatment and management, as a big challenge in the healthcare system.
The Foundation also unveiled its open source philanthropic non fungible token, Phomax NFT. The developer, Phomax NFT, Desmond Bassey, stated this at a media briefing in Benin City, while announcing activities for coming medical outreach of the organisation targeted at providing medical care for glaucoma cases in the state.
He called on Nigerians to go for regular eye checks for early detection of glaucoma for easy management and treatment of the disease, saying: “Glaucoma is a serious disease that easily lead to blindness if not detected early and people are not aware that they have it. So, Nigerians should get their eyes checked regularly and know their status because if detected early, it can be managed but late detention causes blindness.”
He lamented that Nigeria has few ophthalmologists, which, he said, is responsible for poor doctor-patient relationship that has translated to poor information about the disease, treatment and management.
According to him, the organisation partners with NGO on the funding of those living with the disease so they can have access to eye doctors, medication and treatment.
He said they work with other organisations through its NFT and makes it possible for sufferers to access clinics, doctors, treatment and medication through its partners in United Kingdom.
“Currently, 1,000 have benefit from our programme and before now we look at people of about 60 years, but the young and aged are going to benefit from the current medical outreach coming up in Benin.
He charged the government at all levels to do more in creating awareness of the disease because many Nigerians are living with the disease and are not aware of their status.
He called for improvement in glaucoma’s patient-doctor relationship so that people would be aware of their status and management of the disease.